Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. (Formula I).
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
November 8, 2022
Assignee:
Janssen Sciences Ireland Unlimited Company Co Cork, IE
Inventors:
David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut